Roche's ipatasertib-Tecentriq combo leads to 73% ORR in TNBC patients

Roche plans to start a Phase III trial this year to evaluate a combination of ipatasertib plus PD-L1 inhibitor Tecentriq atezolizumab and paclitaxel as first-line treatment of metastatic triple-negative breast cancer following a Phase Ib ORR readout for the combo at AACR on Monday.